- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novo Nordisk Bets on Oral Wegovy to Take on Eli Lilly in US Obesity Market

The Wegovy pill could attract new consumers as Novo looks to revive its fortunes after profit warnings and sliding shares in 2025.
Copwnhagen: Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering 1.5 milligram (mg) and 4 mg doses at USD 149 per month for self-paying patients in an intensely competitive weight-loss drug market.
The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly. Lilly awaits U.S. approval for its weight-loss pill, possibly by March.
The Wegovy pill could attract new consumers as Novo looks to revive its fortunes after profit warnings and sliding shares in 2025. The pill offers consumers a more flexible regime and an alternative for those who dislike needles used in injectable medication.
LURING CASH CUSTOMERS LIKELY TO HELP PILL'S SUCCESS
A key part to success for the pill will be attracting cash-paying consumers who cannot get insurance coverage, a stark shift from the dominant business model where drug pricing is managed through health insurance plans.
Also Read: Eli Lilly, Novo Nordisk race to lock in India obesity drug market
Novo's pill will also be sold in 9 mg and a higher long-term dose of 25 mg. The drugmaker's website, which revealed the pill launch on Monday, showed that the two higher doses will be priced at $299 for a month's supply, while the 4 mg dose will rise to $199 from April 15.
Lilly has said it plans to cap higher doses of its obesity pill at $399 a month for repeat cash buyers. Lilly's injectable drug Zepbound has largely been ahead of Novo's Wegovy in weekly U.S. prescriptions over the past year.
Novo's pill contains semaglutide, the active ingredient found in its blockbuster injectable weight loss and obesity treatments, marketed under the brand names Wegovy and Ozempic.
Novo already sells an oral semaglutide for type 2 diabetes under the brand name Rybelsus.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

